Loading clinical trials...
Loading clinical trials...
A Retrospective/Prospective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma
To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Good Samaritan University Hospital
West Islip, New York, United States
Start Date
January 2, 2024
Primary Completion Date
July 2, 2026
Completion Date
July 2, 2026
Last Updated
April 25, 2025
100
ESTIMATED participants
Blood sample
OTHER
Lead Sponsor
Roswell Park Cancer Institute
NCT04657068
NCT06445062
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions